XENOISLET

Macroencapsulated Porcine Pancreatic Islets to cure Diabetes Mellitus type 1/2

 Coordinatore UNIVERSITE CATHOLIQUE DE LOUVAIN 

 Organization address address: Place De L'Universite 1
city: LOUVAIN LA NEUVE
postcode: 1348

contact info
Titolo: Prof.
Nome: Pierre
Cognome: Gianello
Email: send email
Telefono: +32 2 7645586
Fax: +32 2 7645589

 Nazionalità Coordinatore Belgium [BE]
 Totale costo 6˙419˙746 €
 EC contributo 5˙037˙148 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-2
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-09-01   -   2016-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITE CATHOLIQUE DE LOUVAIN

 Organization address address: Place De L'Universite 1
city: LOUVAIN LA NEUVE
postcode: 1348

contact info
Titolo: Prof.
Nome: Pierre
Cognome: Gianello
Email: send email
Telefono: +32 2 7645586
Fax: +32 2 7645589

BE (LOUVAIN LA NEUVE) coordinator 1˙641˙678.90
2    BIOTALENTUM TUDASFEJLESZTO KFT

 Organization address address: AULICH LAJOS UTCA 26
city: GOEDOELLO
postcode: 2100

contact info
Titolo: Prof.
Nome: Andras
Cognome: Dinnyes
Email: send email
Telefono: +3620 5109632
Fax: +36 28526243

HU (GOEDOELLO) participant 971˙000.00
3    AVANTEA srl

 Organization address address: via Cabrini 12
city: Cremona
postcode: 26100

contact info
Titolo: Dr.
Nome: Giovanna
Cognome: Lazzari
Email: send email
Telefono: +39 0372437242
Fax: +39 0372436133

IT (Cremona) participant 914˙500.00
4    "AVIDIN KUTATO, FEJLESZTO ES KERESKEDELMI KTF"

 Organization address address: ALSO KIKOTO SOR 11
city: SZEGED
postcode: 6726

contact info
Titolo: Dr.
Nome: Laszlo
Cognome: Puskas
Email: send email
Telefono: +3630 6765384
Fax: +3662 202 108

HU (SZEGED) participant 778˙309.10
5    THE GLASGOW CALEDONIAN UNIVERSITY

 Organization address address: "Cowcaddens Road, City Campus 70"
city: GLASGOW
postcode: G4 0BA

contact info
Titolo: Dr.
Nome: Linda
Cognome: Scobie
Email: send email
Telefono: +44141 331 8534
Fax: +44 141 331 3208

UK (GLASGOW) participant 731˙660.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

vivo    pigs    islet    demonstrated    neonates    expressing    transgenic    expression    glp    islets    pig    primates    diabetes    cells    insulin    cell    vitro   

 Obiettivo del progetto (Objective)

'During the last five years, within the EU FP6 Integrated Project XENOME (LSHB-CT-2006-037377), we have convincingly demonstrated in primates that a complete control of induced type 1 diabetes is routinely obtained for 6/8 months after transplantation of subcutaneous alginate macroencapsulated porcine islets xenograft without the use of any immunosuppression. In order to improve the function of pig islets, we have produced with AVANTEA a transgenic pig expressing GLP-1 at the level of the pig islets. In fact, GLP1 is not only able to (i) increase the insulin gene expression and insulin biosynthesis, but also to (ii) induce the replication of islet cells and promotes islet-cell neogenesis and (iii) protect islets cells from apoptosis. GLP-1 has already demonstrated its in vivo potential to improve insulin secretion in subjects with impaired glucose tolerance and type 2 diabetes. The main objectives of this three-year project will therefore be (1) to evaluate in vitro the effect of GLP1 transgene expression in pig islets after hyperglycaemic challenge; (2) to continue to produce transgenic pigs specifically expressing GLP-1 in pig islets under insulin promoter, and (3) finally to test these modified pig islets in our well characterized pig-to-diabetic primates model in vivo. However, in order to use islets from newborn unmodified or transgenic pigs, we will also set up (4) the pig islets isolation and cell maturation technique for Neonates Pancreatic Pig Cluster cells since neonates pig islets have prolonged survival and would also render possible the use of Designed Pathogen Free (DPF) neonates pigs which will represent a key point to reach clinical studies. BIOT will be mainly involved in this part of the work which is in vitro purification, amplification of NPCCS. GCU and AVIDIN Ltd will together develop arrays and a set of molecular testing for pig cell pathogens. A pilot study for safety will be achived whether all the prerequisite are achieved within the third year.'

Altri progetti dello stesso programma (FP7-HEALTH)

MDDANEURODEV (2009)

Molecular coding and subset specification of dopamine neurons generating the the meso-limbic and nigro-striatal system

Read More  

FIT FOR HEALTH (2010)

Promoting participation of high-tech research-intensive SMEs in Health

Read More  

BIOSHARE-EU (2010)

Biobank Standardisation and Harmonisation for Research Excellence in the European Union

Read More